Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy

Nouf H. Alsubhi(King Abdulaziz University), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Stephen Chan(Heidelberg University), Tarek M.A. Abdel-Fatah(University of Nottingham), Ian O. Ellis(University of Nottingham), Reem Ali(Hamad bin Khalifa University), Andrew R. Green(Nottingham Biomedical Research Centre)
Breast Cancer Research and Treatment
February 2, 2018
10.1007/s10549-018-4683-4
Cited by 30

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639